Lantheus
About
Lantheus is a radiopharmaceutical company based in Bedford, built around the idea of helping to find, fight and follow disease. It develops, manufactures and commercializes radiodiagnostic imaging agents and is expanding into radiotherapeutics for cancer. Its products include PYLARIFY, a PET imaging agent used in prostate cancer, the DEFINITY ultrasound enhancing agent used in heart imaging, and Neuraceq, an imaging agent used in evaluating Alzheimer’s disease.
The company traces its roots to New England Nuclear, founded in 1956. That business passed through DuPont, the DuPont Merck venture and Bristol-Myers Squibb before Avista Capital Partners bought the medical imaging unit and Lantheus Medical Imaging launched. Along the way it introduced the TechneLite generator and Cardiolite. More recent milestones include its merger with Progenics Pharmaceuticals and approval of its Billerica manufacturing site for DEFINITY.
What to Know
- Lantheus Holdings trades on the NASDAQ under the ticker LNTH.
- PYLARIFY AI is an artificial intelligence platform that assists with standardized quantification of PSMA.
- The company entered an in-license agreement with POINT Biopharma.
- Its product history also includes RELISTOR, sold as an injection and as tablets.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.